US-based CytImmune gears up to target cancer cure

We all know there is no magic bullet for cancer. But scientists across the world are working on novel projects like cancer vaccines and newer tools like nanotechnology to conquer cancer, reports CNBC-TV18.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney master your money IThe Winning Leap SME Special
Moneycontrol

Home » News » Business

Jun 18, 2007, 07.26 PM | Source: CNBC-TV18

US-based CytImmune gears up to target cancer cure

We all know there is no magic bullet for cancer. But scientists across the world are working on novel projects like cancer vaccines and newer tools like nanotechnology to conquer cancer, reports CNBC-TV18.

Like this story, share it with millions of investors on M3

US-based CytImmune gears up to target cancer cure

We all know there is no magic bullet for cancer. But scientists across the world are working on novel projects like cancer vaccines and newer tools like nanotechnology to conquer cancer, reports CNBC-TV18.

Post Your Comments

Share Cancel

US-based CytImmune gears up to target cancer cure
We all know there is no magic bullet for cancer . But scientists across the world are working on novel projects like cancer vaccines and newer tools like nanotechnology to conquer cancer, reports CNBC-TV18.
 
CytImmune is a small US-based nanotechnology company , but it has set a big goal for itself. CytImmune scientists are developing a nanotechnology-based Drug Delivery System that can target cancerous tumours leaving healthy organs and tissues untouched.

Dr Larry Tamarkin , CEO , Cytimmune, says, “These particles are especially designed with our proprietary technology.”
 
If all goes well in the human trials, CytImmune could provide leads to more precision-based cancer therapies. This is because most experts feel the biggest drawback of most anti-cancer drugs is that they tend to damage healthy tissues. These drugs may not really be targetted therapies as suggested by companies.

Several drug makers like Novartis , Merck and Genentech are also working on a few therapeutic vaccines that can induce the patients’ own immune system to act on the deadly cancer cells.

Elmar Schenny , CEO , Merck Germany , says, “It is in phase III and help attack tumours.”

With the help of genomics and proteomics, experts say over the next few years, it will be easier to see a real headway in predicting and curing cancer.

Buy, Hold, Sell ? Hear it first on M3
US-based CytImmune gears up to target cancer cure

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login